Impact of Tissue Plasminogen Activator on the Neurovascular Unit: From Clinical Data to Experimental Evidence | Zendy

Denis Vivien | Zendy; Maxime Gauberti | Zendy; Axel Montagne | Zendy; Gilles Defer | Zendy; Emmanuel Touzé | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Tissue Plasminogen Activator on the Neurovascular Unit: From Clinical Data to Experimental Evidence

Author(s) -

Denis Vivien,

Maxime Gauberti,

Axel Montagne,

Gilles Defer,

Emmanuel Touzé

Publication year - 2011

Publication title -

journal of cerebral blood flow and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.167

H-Index - 193

eISSN - 1559-7016

pISSN - 0271-678X

DOI - 10.1038/jcbfm.2011.127

Subject(s) - neurovascular bundle , medicine , recombinant tissue plasminogen activator , stroke (engine) , intensive care medicine , tissue plasminogen activator , plasminogen activator , health care , ischemia , ischemic stroke , surgery , mechanical engineering , modified rankin scale , engineering , economics , economic growth

About 15 million strokes occur each year worldwide. As the number one cause of morbidity and acquired disability, stroke is a major drain on public health-care funding, due to long hospital stays followed by ongoing support in the community or nursing-home care. Although during the last 10 years we have witnessed a remarkable progress in the understanding of the pathophysiology of ischemic stroke, reperfusion induced by recombinant tissue-type plasminogen activator (tPA—Actilyse) remains the only approved acute treatment by the health authorities. The objective of the present review is to provide an overview of our present knowledge about the impact of tPA on the neurovascular unit during acute ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research